Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
HIV-1, strain HTLV-III, propagated in H9 cells and purified by sucrose gradient centrifugation, was used as native antigen source for the preparation of immunostimulating complexes, HIV-iscoms. The major antigen detected in the iscom was the cell-derived HLA-DR, which readily could be removed from the virus lysate by immunosorbent. In the iscoms the HIV structural proteins MA p17, p55 and TM gp41 were identified; SU gp120 was present in only minute amounts in the virus lysate. The iscom particles appeared well preserved after freeze drying with a round shape, approximately 35 nm in diameter, comprising morphological subunits, assembled with icosahedral symmetry. Immunization experiments in mice reflected the antigen content of the iscoms. High antibody response was induced to HLA-DR in non-depleted iscoms. Major humoral responses were observed to the viral structural proteins MA p17, CA p24, p55, and also to TM gp41. A low or negligible antibody response to SU gp120 was induced by the HIV-iscoms. The negligible response was, however, overcome by the addition of recombinant gp160 to the virus lysate prior to formation of iscoms, resulting in a preparation evoking a clear serum antibody to gp160.
Höglund
S
S
Institute of Biochemistry, Biomedical Center, Uppsala, Sweden.
Akerblom
L
L
Ozel
M
M
Villacres
M
M
Eriksson
M
M
Gelderblom
H R
HR
Arthur
L
L
Morein
B
B
D000818:Animals; D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D004591:Electrophoresis, Polyacrylamide Gel; D015686:Gene Products, env / Q000008:administration & dosage / Q000276:immunology; D015683:Gene Products, gag / Q000008:administration & dosage / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015488:HIV Antigens / Q000008:administration & dosage / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D051379:Mice; D011498:Protein Precursors / Q000008:administration & dosage / Q000276:immunology; D062605:Quillaja Saponins; D011994:Recombinant Proteins; D012503:Saponins; D014764:Viral Proteins; D014765:Viral Vaccines / Q000276:immunology*; D054301:gag Gene Products, Human Immunodeficiency Virus
D000911:Antibodies, Monoclonal; D015686:Gene Products, env; D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41; D006684:HLA-DR Antigens; D011498:Protein Precursors; D062605:Quillaja Saponins; D011994:Recombinant Proteins; D012503:Saponins; D014764:Viral Proteins; D014765:Viral Vaccines; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1; C059767:p55 gag precursor protein, Human immunodeficiency virus 1; C046386:Quil A